Immune cell therapy trang 1 tải miễn phí từ tailieunhanh

"Immune cell therapy" trang 1 - tải miễn phí từ tailieunhanh

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

10 6 1

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: A case report

8 22 1

The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma

11 77 1

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression≥50%

12 1 1

Association between the efcacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: A retrospective study

10 1 1

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

16 37 1

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer

18 74 1

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study

9 29 1

Immune cells expansion from peripheral blood of some Vietnamese cancer patients

11 50 1

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL‑INDIA)

13 1 1

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer

10 19 1

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: A real-world data analysis

9 1 1

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: A case report

7 1 1

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study

6 1 1

Báo cáo y học: " Chitosan Interferon-c Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses"

11 66 0

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation

10 74 0

Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma

19 29 1

$Hypofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: Study protocol of the phase I HYDRA trial$

Hypofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: Study protocol of the phase I HYDRA trial

8 7 1

Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

5 1 1

A composite biomarker of neutrophillymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

11 18 1